ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.
Registry-linked trialOpen access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04015622 (A Randomized Phase II Trial Comparing Biomarker Directed Therapy Versus Clinician's Choice of Enzalutamide or Docetaxel in Patients With Advanced Prostate Cancer Post Abiraterone), which is not on this map. Cited by 49 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
7.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT04015622 phase2active not recruitingnot on this mapstarted 2020, after this paper: background citation
A Randomized Phase II Trial Comparing Biomarker Directed Therapy Versus Clinician's Choice of Enzalutamide or Docetaxel in Patients With Advanced Prostate Cancer Post Abiraterone
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Neoadjuvant treatment with androgen receptor signaling inhibitors prior to radical prostatectomy: a systematic review.World journal of urology · 2021Pooled it
- Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study.Cell reports. Medicine · 2025Trial
- Trial
- A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Trial
- Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA-Targeted Tubulysin Conjugate EC1169.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Sparse-Input Neural Network using Group Concave Regularization.Transactions on machine learning research · 2025Article
- Variable Selection for Multivariate Failure Time Data via Regularized Sparse-Input Neural Network.Bioengineering (Basel, Switzerland) · 2025Article
- The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages.International journal of molecular sciences · 2025Review
- Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer.Scientific reports · 2024Article
- Defining biology and recurrence risk in prostate cancers treated by neoadjuvant chemohormonal therapy.Journal of the National Cancer Institute · 2024Article
- Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial.Journal of the National Cancer Institute · 2024Article
- Cell-by-cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression.The journal of pathology. Clinical research · 2023Article
- Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review.Journal of personalized medicine · 2023Review
- Article
- Targeting the radiation-induced ARv7-mediated circNHS/miR-512-5p/XRCC5 signaling with Quercetin increases prostate cancer radiosensitivity.Journal of experimental & clinical cancer research : CR · 2022Article
- Article
- Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer.Scientific reports · 2022Article
- ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer.Nature communications · 2022Article
- Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer-Where Are We Now?Cancers · 2022Review
- Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors.Advanced materials (Deerfield Beach, Fla.) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 3 countries.
Himisha BeltranDivision of Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, New York. hip9004@med.cornell.edu m.gleave@ubc.ca.
Alexander W WyattVancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Edmund C ChedgyVancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Adam DonoghueDivision of Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, New York.
Matti AnnalaInstitute of Biosciences and Medical Technology, University of Tampere, Tampere, Finland.
Evan W WarnerVancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Kevin BejaVancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Michael SigourosDivision of Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, New York.
Fan MoVancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Ladan FazliVancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Colin C CollinsVancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
James EasthamDepartment of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Michael MorrisDepartment of Medical Oncology, Dana-Farber/Partners Cancer Care, Boston, Massachusetts.
Mary-Ellen TaplinDepartment of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York New York.
Andrea SbonerDepartment of Urology, Memorial Sloan Kettering Cancer Center, New York, New York.
Susan HalabiAlliance Statistics and Data Center and Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina.
Martin E GleaveVancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. hip9004@med.cornell.edu m.gleave@ubc.ca.
University of British Columbia · CACornell University · USMemorial Sloan Kettering Cancer Center · USDana-Farber Cancer Institute · USDuke University · USTampere University of Applied Sciences · FI
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MMember Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3MCANCER AND LEUKEMIA GROUP B MINORITY SATELLITE SUPPLEMENU10CA031946 · NCI · UNIVERSITY OF CHICAGO · PI BERTAGNOLLI, MONICA M · 1985 to 2013
$158.4MNCIC Clinical Trials Group - Canadian Collaborating Clinical Trials NetworkU10CA180863 · NCI · QUEEN'S UNIVERSITY AT KINGSTON · PI Janet Ellen Dancey · 2014 to 2026
$40.4MNCIC Foreign AccrualsU10CA077202 · NCI · QUEEN'S UNIVERSITY AT KINGSTON · PI EISENHAUER, ELIZABETH · 1998 to 2013
$14.6MNCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareU10CA180867 · NCI · DANA-FARBER CANCER INST · PI BURSTEIN, HAROLD JOHN, KIBEL, ADAM S · 2014 to 2018
$6.2MValidation of prognostic and pathway signatures in lethal prostate cancerU01CA157703 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GLEAVE, MARTIN EDWIN, HALABI, SUSAN · 2011 to 2015
$2.5MNCI NIH HHS P30 CA008748NCI NIH HHS U01 CA157703NCI NIH HHS U10 CA031946NCI NIH HHS U10 CA077202NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180863NCI NIH HHS U10 CA180867
Abstract
PubMed holds no abstract for this paper.
Indexed as
GenomicsTranscriptomeAndrogen Receptor AntagonistsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBiopsy, NeedleCombined Modality TherapyDocetaxelGene Expression Regulation, NeoplasticHumansMaleMiddle AgedMutationNeoadjuvant TherapyNeoplasm GradingNeoplasm MetastasisAndrogen Receptor AntagonistsBiomarkers, TumorDocetaxelTaxoids
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT04015622ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.